Cenovus Energy Inc vs Novartis AG — how do they compare? Cenovus Energy Inc trades at $27.59 (market cap $50.90B), while Novartis AG trades at $149.88 (market cap $288.65B). The key difference: Novartis AG is far larger — about 5.7× Cenovus Energy Inc's market cap, and Novartis AG pays the higher dividend (3.15%). Which is the better fit depends on your goals.
| CVE | NVS | |
|---|---|---|
Market Cap | $50.90B | $288.65B |
Sector | Energy | Health |
52-Week High | $31.80 | $168.62 |
52-Week Low | $13.96 | $113.50 |
Enterprise Value | $58.77B | $328.67B |
Dividend Yield | 2.25% | 3.15% |
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $27.61, up 4.58% with strong bullish technical indicators and consistent earnings beats. The stock shows solid fundamentals with a P/E of 15.62, ROE of 14.86%, and improving cash flow projections. Recent news highlights benefits from rising crude prices and operational synergies from MEG Energy acquisition.
CVE presents a compelling investment case with attractive valuation, strong profitability metrics, and positive analyst sentiment (40.74% buy ratings). Key risks include oil price volatility and execution challenges in growth projects. The integrated business model provides resilience across energy cycles.
Novartis (NVS) trades at $153.37, down 0.44% today, with a bullish technical signal from moving averages. The company reported $56.67B revenue in 2025 with strong profitability margins (net income margin 23.92%) and recently expanded its oncology pipeline through acquisitions like Myricx Bio. Earnings have been mixed, with a miss in Q1 2026 but a beat in Q4 2025.
Outlook remains stable with revenue projections near $56.6B for 2026, though debt-to-asset ratio has risen to 30.26%. Risks include pipeline execution and competitive pressures. Analysts show cautious optimism with 68% hold ratings, reflecting balanced growth and valuation concerns.
Trailing returns across standard periods
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →